Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SANA vs ZVRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ZVRA Overall Winner 6-Pillar Tally: SANA 1 – 5 ZVRA Matrix Metrics: SANA 2 – 8 ZVRA

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas ZVRA carries 49.4/100 (HOLD) at $9.25 (10.4x Forward P/E, 31.5% operating margin).

  • Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile ZVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SANA vs ZVRA
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68
ZVRA NASDAQ Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.25
+1.87% 1D
Market Cap $540.3M
TTM Revenue $148M
Forward P/E 10.4x
Beta / 30D Vol 1.19β · 94% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 39
RSI-14: 38.9 · SMA20: $10.53 · SMA50: $10.92

6-Pillar Scorecard Institutional Category Breakdown (SANA 1 – 5 ZVRA)

Columns: Metric · SANA · ZVRA
1. Valuation Multiples ZVRA
Forward P/E N/M 10.4x
Trailing P/E N/M 7.4x
PEG Ratio N/M 10.67x
EV / Revenue N/M 2.8x
2. Growth & Scale ZVRA
Revenue Growth (YoY) +0.0% +44.9%
Earnings Growth (YoY) +0.0% -88.4%
TTM Revenue (USD) N/A $148M
Market Cap $605.3M $540.3M
3. Profitability & Quality ZVRA
Gross Margin N/A 95.4%
Operating Margin 0.0% 31.5%
Net Profit Margin 0.0% 52.8%
Return on Equity (ROE) -79.5% 41.9%
4. Balance Sheet & Cash Flow ZVRA
Cash Generation (TTM) -$145M $38M
Cash Flow Margin N/A 25.9%
Net Cash / Leverage $13M Net Debt (0.30x D/E) $121M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SANA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 105.5% (4th %ile) 82.5% (18th %ile)
Put/Call OI Skew 0.61x (Call-Skewed) 1.62x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ZVRA
OpEx & R&D Intensity N/A 63.9% of Rev ($94M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SANA (2) vs ZVRA (8)
Institutional Metric SANA ZVRA Criterion Row Edge
Market Capitalization
Scale
$605.3M $540.3M Larger Scale SANA
Trailing P/E Ratio
Valuation
N/M 7.4x Lower Multiple ZVRA
Forward P/E Ratio
Valuation
N/M 10.4x Lower Multiple ZVRA
Revenue Growth (YoY)
Growth
+0.0% +44.9% Higher Growth ZVRA
Operating Margin (TTM)
Profitability
0.0% 31.5% Higher Margin ZVRA
Net Profit Margin
Profitability
0.0% 52.8% Higher Margin ZVRA
Return on Equity (ROE)
Capital Efficiency
-79.5% 41.9% Higher ROE ZVRA
52-Week Range Position
Momentum
1% ($2–$5) 18% ($8–$15) Stronger Trend ZVRA
Beta / 30D Volatility
Risk Regime
1.82β · 78% Vol 1.19β · 94% Vol Lower Realized Risk SANA
Unified Institutional Score
Composite Signal
44.3 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZVRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $148M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 95.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.67x PEG · 2.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$145M ($13M Net Debt (0.30x D/E)) $38M ($121M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZVRA +10.24 pp
SANA: -17.18% · ZVRA: -6.94%
3M Horizon ZVRA +28.16 pp
SANA: -48.21% · ZVRA: -20.05%
6M Horizon ZVRA +26.85 pp
SANA: -38.16% · ZVRA: -11.31%
1Y Horizon ZVRA +48.85 pp
SANA: -48.63% · ZVRA: +0.22%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs ZVRA. Trailing 12-month operating profitability (SANA 0.0% vs ZVRA 31.5%) and valuation multiples (SANA N/M vs ZVRA 10.4x Forward P/E) are benchmarked directly in Pillar 4 below.

SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M
ZVRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$148M
Gross Margin95.4%
Op. Margin31.5%
ROE / Fwd P/E41.9% · 10.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZVRA BREAKDOWN
111d in phase · OBV DISTRIBUTION
Current IV 82.5%
IV Percentile 18th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZVRA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $540.3M market capitalization and 31.5% operating margin.
OpEx & R&D Reinvestment 63.9% of Rev ($94M)
90D Engineering Disclosures 0 Published

Investor FAQ SANA vs ZVRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas ZVRA carries 49.4/100 (HOLD) at $9.25 (10.4x Forward P/E, 31.5% operating margin). Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile ZVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZVRA leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ZVRA at +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $148M for ZVRA. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus 63.9% of Rev ($94M) (0 disclosures) for ZVRA.

ZVRA screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ZVRA trades at 10.4x Forward P/E, 7.4x Trailing P/E, 10.67x PEG, and 2.8x EV/Revenue (25.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus ZVRA (41.9% ROE) capital efficiency.

In options market volatility and institutional positioning, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, ZVRA carries 82.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.